Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Moderna (MRNA) Stock Price & Analysis

19,045 Followers

MRNA Stock Chart & Stats

$254.19$12.73(5.27%)
At close: 4:00 PM EST
$100$200Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$237.86 - $267.50
52-Week Range
$22.28 - $267.50
Previous Close
$241.46
Volume
N/A
Average Volume (3M)
17.46M
Market Cap
$101.48B
Enterprise Value
$81.86B
Total Cash (Recent Filing)
$5.17B
Total Debt (Recent Filing)
$4.18B
Price to Earnings (P/E)
―
Beta
0.80
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
-2.01
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Expanding Vaccine Portfolio

The expanding respiratory portfolio reduces reliance on a single COVID product and creates additional commercial opportunities across influenza, COVID, and combination vaccines. Multiple approvals also provide a broader platform for recurring seasonal demand and international market penetration.

Improving Revenue Outlook

A materially higher revenue framework indicates stronger commercial execution, demand, and shipment expectations than previously anticipated. If sustained, this growth can improve operating leverage, support pipeline investment, and help rebuild earnings power across a more diversified product base.

Oncology Pipeline Validation

Positive Phase 3 melanoma data provide important clinical validation for Moderna's individualized cancer-vaccine approach and could support a meaningful expansion beyond infectious diseases. The result also strengthens the strategic value of the broader oncology pipeline and future partnership potential.

Bears Say

Persistent Cash Burn

Meaningfully negative operating and free cash flow leave Moderna dependent on existing liquidity or external financing while its portfolio matures. Continued burn can restrict investment flexibility, weaken resilience during delays, and make a sustained return to profitability more important.

Large Ongoing Losses

The current revenue base does not yet support Moderna's cost structure, as substantial operating expenses continue to produce a large net loss. Unless revenue growth and cost discipline persist together, earnings volatility and prolonged losses could erode financial flexibility and shareholder returns.

Clinical Development Setbacks

Failure to meet interim success criteria highlights uncertainty in converting Moderna's mRNA platform into consistently successful products. The setback may delay a potential commercial opportunity, redirect development resources, and increase dependence on respiratory products and oncology milestones.

Moderna News

MRNA FAQ

What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $267.50 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $101.48B.
When is Moderna’s upcoming earnings report date?
Moderna’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 109 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Nov 06, 2026. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of -$1.096 by $1.476.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.01.
How many shares outstanding does Moderna have?
Moderna has 399,235,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of $0.38 in its last earnings report, beating expectations of -$1.096. Following the earnings report the stock price went up 5.272%.
Which hedge fund is a major shareholder of Moderna?
Hedge funds hold Moderna shares: the largest hedge-fund position in Moderna is 71,885,897 shares, and hedge funds increased their holdings by 913.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology